ANN ARBOR, Mich., April 25 2017 - Genomenon® Inc., a genomic interpretation software company, today announced a $1.8M grant awarded by the National Institutes of Health. The fast-track Small Business Innovation Research (SBIR) grant, awarded by the National Human Genome Research Institute, will fund Genomenon’s further innovation in genomic analysis, efficiently streamlining the laborious literature research and curation process leading to faster patient diagnosis.
“This grant recognizes the solid approach and great potential of Genomenon’s technology to drive rapid improvements in automating accurate gene and variant curation” Genomenon cofounder and CSO Dr. Mark Kiel said.
Genomenon’s initial product, Mastermind, is a novel analytic and data visualization tool that accelerates gene and variant curation by providing immediate insight into millions of scientific articles from the primary medical literature. The grant will help Genomenon in its quest to assemble the most comprehensive database of genomic knowledge ever created by expanding its Mastermind database with millions of additional articles covering genetic disease.
The funds for Phase I of this grant will be used to perform concordance testing between the Mastermind database and current gold-standard references of genomic knowledge. Phase II will focus on refining various applications using the Mastermind database including the development of ancillary software to inform patient diagnosis and research discovery.
Genomenon recently announced the completion of its latest financing round in the 4th quarter of 2016. The financing fueled the completion and launch of Mastermind, which was officially released in February.
Research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R44HG009474. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is buried in 39 million biomedical articles, locked behind paywalls and supplemental files most researchers never find.
Genomenon closes that gap. Fit-for-purpose AI-powered search reads 11.2 million full-text papers and 3.7 million supplemental datasets. Eighty expert scientific curators validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. Loxo@Lilly used Genomenon to add 73 variants to the RET label. In a head-to-head, Genomenon identified 83% more rare disease patients than ChatGPT plus OpenEvidence.
250+ diagnostic labs and 75 biopharma programs rely on Genomenon as the evidence layer behind precision medicine.
